IMMATICS NV (IMTX) Stock News

NASDAQ:IMTX - Nasdaq - NL0015285941 - Common Stock - Currency: USD

6 -0.21 (-3.38%)

After market: 6 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IMTX Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Yahoo Finance - Mentions: DB

Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)

2 months ago - By: https://immatics.com/

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

2 months ago - By: https://immatics.com/

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

2 months ago - By: https://immatics.com/

Immatics Announces First Quarter 2025 Financial Results and Business Update

2 months ago - By: https://immatics.com/

Immatics Announces First Quarter 2025 Financial Results and Business Update

2 months ago - By: Zacks Investment Research - Mentions: IBRX

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: CRDF

Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: DAWN

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates

a year ago - By: BusinessInsider

News Image

IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q2 2024

3 months ago - By: https://immatics.com/

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

3 months ago - By: https://immatics.com/

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

3 months ago - By: Yahoo Finance - Mentions: PLTR AAPL USB

Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds?

4 months ago - By: https://immatics.com/

Immatics Announces Full Year 2024 Financial Results and Business Update

4 months ago - By: https://immatics.com/

Immatics Announces Full Year 2024 Financial Results and Business Update

7 months ago - By: Benzinga - Mentions: CYCC AHG ONCO EYEN ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

8 months ago - By: https://immatics.com/

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

8 months ago - By: https://immatics.com/

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

8 months ago - By: https://immatics.com/

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

8 months ago - By: https://immatics.com/

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

9 months ago - By: https://immatics.com/

Immatics Announces Pricing of $150 Million Public Offering

9 months ago - By: https://immatics.com/

Immatics Announces Pricing of $150 Million Public Offering

9 months ago - By: Benzinga

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

9 months ago - By: https://immatics.com/

Immatics Announces Proposed $150 Million Public Offering

9 months ago - By: https://immatics.com/

Immatics Announces Proposed $150 Million Public Offering

9 months ago - By: https://immatics.com/

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

9 months ago - By: https://immatics.com/

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

10 months ago - By: https://immatics.com/

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

10 months ago - By: https://immatics.com/

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

10 months ago - By: https://immatics.com/

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

10 months ago - By: https://immatics.com/

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

11 months ago - By: https://immatics.com/

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

11 months ago - By: https://immatics.com/

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024